Gregor K Wenning

List of Publications by Citations

245 papers	14,412 citations	60 h-index	116 g-index
280 ext. papers	17,149 ext. citations	6.8 avg, IF	6.38 L-index

#	Paper	IF	Citations
245	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Movement Disorders*, **2004**, 19, 1020-8	7	1259
244	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. *Movement Disorders*, **2017**, 32, 853-864	7	840
243	The diagnosis of Parkinson's disease. *Lancet Neurology, The*, **2006**, 5, 75-86	24.1	476
242	Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. *Glia*, **2013**, 61, 349-60	9	422
241	Multiple-system atrophy. *New England Journal of Medicine*, **2015**, 372, 249-63	59.2	401
240	Multiple system atrophy. *Lancet Neurology, The*, **2004**, 3, 93-103	24.1	377
239	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). *Movement Disorders*, **2004**, 19, 1391-402	7	372
238	The natural history of multiple system atrophy: a prospective European cohort study. *Lancet Neurology, The*, **2013**, 12, 264-74	24.1	322
237	Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. *Archives of Neurology*, **2001**, 58, 259-64		291
236	How to diagnose dementia with Lewy bodies: state of the art. *Movement Disorders*, **2005**, 20 Suppl 12, S11-20	7	255
235	Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. *Clinical Autonomic Research*, **1998**, 8, 359-62	4.3	248
234	Multiple system atrophy: a primary oligodendrogliopathy. *Annals of Neurology*, **2008**, 64, 239-46	9.4	239
233	SNCA variants are associated with increased risk for multiple system atrophy. *Annals of Neurology*, **2009**, 65, 610-4	9.4	232
232	Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. *American Journal of Pathology*, **2011**, 179, 954-63	5.8	189
231	Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. *Movement Disorders*, **2007**, 22, 2196-203	7	179
230	Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. *American Journal of Pathology*, **2005**, 166, 869-76	5.8	173
229	Red flags for multiple system atrophy. *Movement Disorders*, **2008**, 23, 1093-9	7	168

228	Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. *Movement Disorders*, **2010**, 25, 2604-12	7	155
227	Glial dysfunction in the pathogenesis of □synucleinopathies: emerging concepts. *Acta Neuropathologica*, **2011**, 121, 675-93	14.3	149
226	Cognitive impairment in multiple system atrophy: a position statement by the Neuropsychology Task Force of the MDS Multiple System Atrophy (MODIMSA) study group. *Movement Disorders*, **2014**, 29, 857-67	7	148
225	Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). *Movement Disorders*, **2010**, 25, 97-107	7	136
224	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. *Movement Disorders*, **2003**, 18, 1132-8	7	135
223	Grading of neuropathology in multiple system atrophy: proposal for a novel scale. *Movement Disorders*, **2005**, 20 Suppl 12, S29-36	7	132
222	Glia and alpha-synuclein in neurodegeneration: A complex interaction. *Neurobiology of Disease*, **2016**, 85, 262-274	7.5	128
221	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson□s disease. *NeuroImage*, **2004**, 21, 1443-51	7.9	127
220	Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **1997**, 24, 320-5		123
219	Progression of falls in postmortem-confirmed parkinsonian disorders. *Movement Disorders*, **1999**, 14, 947-50	7	122
218	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. *Nature Communications*, **2015**, 6, 7247	17.4	118
217	Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). *Movement Disorders*, **2006**, 21, 179-86	7	114
216	Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. *Archives of Neurology*, **2009**, 66, 742-50		113
215	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPECT study using 123I-beta-CIT and 123I-IBZM. *European Journal of Nuclear Medicine and Molecular Imaging*, **2000**, 27, 1410-4		109
214	Premotor signs and symptoms of multiple system atrophy. *Lancet Neurology, The*, **2012**, 11, 361-8	24.1	108
213	Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson□s disease. *Brain*, **2005**, 128, 1605-12	11.2	102
212	Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). *Clinical Autonomic Research*, **2018**, 28, 355-362	4.3	102
211	Iron in Neurodegeneration - Cause or Consequence?. *Frontiers in Neuroscience*, **2019**, 13, 180	5.1	101

210	Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. *Journal of Neurology*, **2007**, 254, 191-6	5.5	100
209	Multiple system atrophy: insights into a rare and debilitating movement disorder. *Nature Reviews Neurology*, **2017**, 13, 232-243	15	96
208	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. *Movement Disorders*, **2015**, 30, 1068-76	7	96
207	Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. *Neurology*, **2015**, 85, 1761-8	6.5	94
206	Survival in multiple system atrophy. *Movement Disorders*, **2008**, 23, 294-6	7	91
205	The role of alpha-synuclein in the pathogenesis of multiple system atrophy. *Acta Neuropathologica*, **2005**, 109, 129-40	14.3	87
204	Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. *NeuroImage*, **2006**, 31, 240-5	7.9	84
203	Health-related quality of life in multiple system atrophy. *Movement Disorders*, **2006**, 21, 809-15	7	83
202	Recent developments in multiple system atrophy. *Journal of Neurology*, **2009**, 256, 1791-808	5.5	81
201	Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. *Movement Disorders*, **2004**, 19, 1438-45	7	78
200	Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. *Journal of Neurology*, **2013**, 260, 2212-9	5.5	77
199	Glial cell death induced by overexpression of alpha-synuclein. *Journal of Neuroscience Research*, **2001**, 65, 432-8	4.4	77
198	A validation exercise on the new consensus criteria for multiple system atrophy. *Movement Disorders*, **2009**, 24, 2272-6	7	76
197	Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. *Neurotoxicity Research*, **2012**, 21, 393-404	4.3	75
196	Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). *Archives of Neurology*, **2011**, 68, 223-30		73
195	Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. *Movement Disorders*, **2007**, 22, 1771-6	7	73
194	Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. *Journal of Neuroscience Research*, **2009**, 87, 2728-39	4.4	71
193	Animal models of multiple system atrophy. *Trends in Neurosciences*, **2005**, 28, 501-6	13.3	71

192	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurology, The*, **2015**, 14, 145-52	24.1	69
191	Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection. *PLoS ONE*, **2011**, 6, e19808	3.7	69
190	Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. *Experimental Neurology*, **2008**, 210, 421-7	5.7	68
189	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human -synuclein under oligodendrocyte promoter: implications for multiple system atrophy. *Acta Neuropathologica*, **2012**, 124, 51-65	14.3	64
188	Supine hypertension in Parkinson's disease and multiple system atrophy. *Clinical Autonomic Research*, **2016**, 26, 97-105	4.3	62
187	Cortical atrophy in the cerebellar variant of multiple system atrophy: a voxel-based morphometry study. *Movement Disorders*, **2006**, 21, 159-65	7	61
186	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. *Neurology*, **2016**, 86, 1242-9	6.5	60
185	Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. *Experimental Neurology*, **2010**, 224, 459-64	5.7	59
184	Milestones in atypical and secondary Parkinsonisms. *Movement Disorders*, **2011**, 26, 1083-95	7	58
183	Multiple system atrophy: an update. *Movement Disorders*, **2003**, 18 Suppl 6, S34-42	7	58
182	Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. *Movement Disorders*, **2003**, 18, 319-323	7	57
181	Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. *Movement Disorders*, **2007**, 22, 1138-44	7	55
180	Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. *Movement Disorders*, **2006**, 21, 847-52	7	55
179	Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal -synucleinopathy. *Molecular Neurodegeneration*, **2017**, 12, 52	19	54
178	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. *Neurobiology of Disease*, **2015**, 80, 29-41	7.5	48
177	Progression of parkinsonism in multiple system atrophy. *Journal of Neurology*, **2005**, 252, 91-6	5.5	47
176	Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. *Experimental Neurology*, **2001**, 167, 133-47	5.7	47
175	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. *Journal of Neural Transmission*, **2017**, 124, 1567-1605	4.3	46

174	Multiple-system atrophy. *New England Journal of Medicine*, **2015**, 372, 1375-6	59.2	46
173	The "cold hands sign" in multiple system atrophy. *Movement Disorders*, **1997**, 12, 514-8	7	46
172	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). *Acta Neuropathologica*, **2003**, 106, 157-66	14.3	46
171	Olivopontocerebellar atrophy: toward a better nosological definition. *Movement Disorders*, **2006**, 21, 1607-13	7	45
170	A critique of the second consensus criteria for multiple system atrophy. *Movement Disorders*, **2019**, 34, 975-984	7	44
169	Bladder dysfunction in a transgenic mouse model of multiple system atrophy. *Movement Disorders*, **2013**, 28, 347-55	7	44
168	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence. *Experimental Neurology*, **2013**, 247, 531-6	5.7	43
167	Multiple system atrophy: pathogenic mechanisms and biomarkers. *Journal of Neural Transmission*, **2016**, 123, 555-72	4.3	43
166	The reorganization of functional architecture in the early-stages of Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 50, 61-68	3.6	42
165	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2019**, 18, 724-735	24.1	42
164	Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. *Movement Disorders*, **2019**, 34, 255-263	7	40
163	123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. *Movement Disorders*, **1998**, 13, 438-45	7	39
162	Freezing of gait in postmortem-confirmed atypical parkinsonism. *Movement Disorders*, **2002**, 17, 1041-5	7	39
161	Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment. *Neurology*, **2019**, 93, 630-639	6.5	38
160	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. *Journal of Neurology*, **2014**, 261, 1291-9	5.5	36
159	Brain structural profile of multiple system atrophy patients with cognitive impairment. *Journal of Neural Transmission*, **2017**, 124, 293-302	4.3	36
158	Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. *Movement Disorders*, **2000**, 15, 531-6	7	36
157	Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 1012-20	8.8	35

156	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. *NeuroReport*, **2004**, 15, 1711-4	1.7	35
155	Multiple system atrophy. *International Review of Neurobiology*, **2019**, 149, 137-192	4.4	35
154	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. *Acta Neuropathologica Communications*, **2018**, 6, 2	7.3	34
153	Placebo-controlled trial of amantadine in multiple-system atrophy. *Clinical Neuropharmacology*, **2005**, 28, 225-7	1.4	34
152	Towards translational therapies for multiple system atrophy. *Progress in Neurobiology*, **2014**, 118, 19-35	10.9	33
151	Genetic players in multiple system atrophy: unfolding the nature of the beast. *Neurobiology of Aging*, **2011**, 32, 1924.e5-14	5.6	33
150	Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein. *Journal of Neuroscience Research*, **2003**, 73, 334-40	4.4	33
149	Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. *Journal of Hypertension*, **2019**, 37, 1541-1546	1.9	33
148	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. *Parkinsonism and Related Disorders*, **2018**, 46, 47-55	3.6	33
147	Therapeutic strategies in multiple system atrophy. *Movement Disorders*, **2005**, 20 Suppl 12, S67-76	7	32
146	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. *Parkinsonism and Related Disorders*, **2018**, 54, 90-94	3.6	29
145	Sensor-based gait analysis in atypical parkinsonian disorders. *Brain and Behavior*, **2018**, 8, e00977	3.4	28
144	Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy?. *Experimental Neurology*, **2009**, 219, 368-71	5.7	27
143	Animal models of multiple system atrophy. *Clinical Autonomic Research*, **2015**, 25, 9-17	4.3	26
142	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. *PLoS ONE*, **2017**, 12, e0189897	3.7	26
141	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. *Journal of Neuroscience Research*, **2004**, 78, 87-91	4.4	26
140	New insights into atypical parkinsonism. *Current Opinion in Neurology*, **2011**, 24, 331-8	7.1	25
139	A novel computer-assisted image analysis of [123I]-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders. *European Journal of Nuclear Medicine and Molecular Imaging*, **2011**, 38, 702-10	8.8	25

138	The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint. *Journal of Alzheimerls Disease*, **2018**, 61, 1253-1273	4.3	24
137	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. *Neuroscience Letters*, **1999**, 274, 61-5	3.3	24
136	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. *Neurotoxicity Research*, **2015**, 28, 185-94	4.3	23
135	Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response. *Journal of Neuroscience Research*, **2009**, 87, 1679-85	4.4	23
134	Non-Motor Symptoms in ParkinsonS Disease are Reduced by Nabilone. *Annals of Neurology*, **2020**, 88, 712-722	9.4	23
133	Cerebral autoregulation and white matter lesions in ParkinsonS disease and multiple system atrophy. *Parkinsonism and Related Disorders*, **2015**, 21, 1393-7	3.6	22
132	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. *Sleep*, **2018**, 41,	1.1	21
131	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. *Journal of Neural Transmission*, **2016**, 123, 439-45	4.3	21
130	Multiple system atrophy. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2013**, 117, 229-41	3	21
129	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. *PLoS ONE*, **2016**, 11, e0150705	3.7	20
128	Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. *Clinical Neurophysiology*, **2021**, 132, 666-682	4.3	20
127	In vitro models of multiple system atrophy. *Movement Disorders*, **2005**, 20 Suppl 12, S53-6	7	19
126	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. *Movement Disorders*, **2022**,	7	19
125	Multiple system atrophy as emerging template for accelerated drug discovery in □synucleinopathies. *Parkinsonism and Related Disorders*, **2014**, 20, 793-9	3.6	18
124	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. *Proteome Science*, **2012**, 10, 71	2.6	18
123	Intact olfaction in a mouse model of multiple system atrophy. *PLoS ONE*, **2013**, 8, e64625	3.7	18
122	Region-Specific Effects of Immunotherapy With Antibodies Targeting □ynuclein in a Transgenic Model of Synucleinopathy. *Frontiers in Neuroscience*, **2018**, 12, 452	5.1	18
121	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. *Parkinsonism and Related Disorders*, **2018**, 49, 81-87	3.6	17

120	Assessing disease progression with MRI in atypical parkinsonian disorders. *Movement Disorders*, **2009**, 24 Suppl 2, S699-702	7	17
119	Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease. *Movement Disorders*, **2019**, 34, 440-441	7	17
118	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. *Movement Disorders*, **2019**, 34, 1041-1048	7	16
117	Sex and age effects on cardiovascular autonomic function in healthy adults. *Clinical Autonomic Research*, **2015**, 25, 317-26	4.3	16
116	Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. *Movement Disorders*, **2000**, 15, 362-3	7	16
115	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. *Frontiers in Neuroscience*, **2016**, 10, 99	5.1	16
114	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent □synuclein in experimental multiple system atrophy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 165513	6.9	15
113	Cognitive impairment in multiple system atrophy. *Movement Disorders*, **2017**, 32, 1338-1339	7	15
112	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. *Alzheimerls and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 301-309	5.2	14
111	Multiple system atrophy: experimental models and reality. *Acta Neuropathologica*, **2018**, 135, 33-47	14.3	14
110	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. *Parkinsonism and Related Disorders*, **2018**, 56, 33-40	3.6	14
109	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. *Movement Disorders*, **2011**, 26, 507-515	7	14
108	Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy). *Experimental Neurology*, **2000**, 164, 166-75	5.7	14
107	The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations. *Frontiers in Neurology*, **2019**, 10, 5	4.1	13
106	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. *Neurotherapeutics*, **2016**, 13, 871-879	6.4	13
105	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. *Parkinsonism and Related Disorders*, **2019**, 67, 60-65	3.6	13
104	Involvement of Peripheral Nerves in the Transgenic PLP-□Syn Model of Multiple System Atrophy: Extending the Phenotype. *PLoS ONE*, **2015**, 10, e0136575	3.7	13
103	An update on the cerebellar subtype of multiple system atrophy. *Cerebellum and Ataxias*, **2014**, 1, 14	1.7	13

102	Models of multiple system atrophy. *Current Topics in Behavioral Neurosciences*, **2015**, 22, 369-93	3.4	13
101	Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. *Movement Disorders*, **2007**, 22, 353-8	7	13
100	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. *Movement Disorders Clinical Practice*, **2020**, 7, 750-762	2.2	13
99	Cognition in multiple system atrophy: a single-center cohort study. *Annals of Clinical and Translational Neurology*, **2020**, 7, 219-228	5.3	12
98	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. *Parkinsonism and Related Disorders*, **2019**, 58, 23-27	3.6	12
97	Distinct Parameters in the EEG of the PLP-SYN Mouse Model for Multiple System Atrophy Reinforce Face Validity. *Frontiers in Behavioral Neuroscience*, **2016**, 10, 252	3.5	12
96	The Unified Multiple System Atrophy Rating Scale: intrarater reliability. *Movement Disorders*, **2012**, 27, 1683-5	7	12
95	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). *Autonomic Neuroscience: Basic and Clinical*, **2021**, 233, 102792	2.4	11
94	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. *Journal of Parkinsonls Disease*, **2019**, 9, 681-691	5.3	10
93	Management of Orthostatic Hypotension in Parkinsonls Disease. *Journal of Parkinsonls Disease*, **2020**, 10, S57-S64	5.3	10
92	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology*, **2018**, 90, 74-82	6.5	10
91	Autonomic function testing in Friedreichls ataxia. *Journal of Neurology*, **2018**, 265, 2015-2022	5.5	10
90	Validation of the Neurogenic Orthostatic Hypotension Ratio with Active Standing. *Annals of Neurology*, **2020**, 88, 643-645	9.4	9
89	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. *Parkinsonism and Related Disorders*, **2020**, 77, 57-63	3.6	9
88	Autonomic function testing in spinocerebellar ataxia type 2. *Clinical Autonomic Research*, **2018**, 28, 341-346	4.9	9
87	Urinary retention discriminates multiple system atrophy from Parkinsonls disease. *Movement Disorders*, **2019**, 34, 1926-1928	7	9
86	Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy. *Journal of Neuroscience Research*, **2012**, 90, 1284-95	4.4	9
85	Gait and postural disorders in parkinsonism: a clinical approach. *Journal of Neurology*, **2020**, 267, 3169-3176	5.5	9

84	Cardiovascular autonomic function testing in multiple system atrophy and Parkinson's disease: an expert-based blinded evaluation. *Clinical Autonomic Research*, **2020**, 30, 255-263	4.3	8
83	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. *Movement Disorders*, **2017**, 32, 1356-1364	7	8
82	Clinically probable multiple system atrophy with predominant parkinsonism associated with myotonic dystrophy type 2. *Movement Disorders*, **2009**, 24, 1407-9	7	8
81	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. *Neurology*, **2020**, 95, e2854-e2865	6.5	8
80	Gender differences in clinical, laboratory and polysomnographic features of restless legs syndrome. *Journal of Sleep Research*, **2020**, 29, e12875	5.8	8
79	Limited effects of dysfunctional macroautophagy on the accumulation of extracellularly derived □synuclein in oligodendroglia: implications for MSA pathogenesis. *BMC Neuroscience*, **2018**, 19, 32	3.2	7
78	Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). *Clinical Autonomic Research*, **2021**, 31, 369-384	4.3	7
77	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. *Movement Disorders*, **2016**, 31, 235-40	7	7
76	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of □synucleinopathy. *Journal of Neuroinflammation*, **2020**, 17, 35	10.1	6
75	Do periodic arm movements during sleep exist in healthy subjects? A polysomnographic study. *Sleep Medicine*, **2014**, 15, 1150-4	4.6	6
74	An early report of striatonigral degeneration. *Movement Disorders*, **2000**, 15, 159-62	7	6
73	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. *Movement Disorders*, **2016**, 31, 1577-1581	7	6
72	SYNE1-ataxia: Novel genotypic and phenotypic findings. *Parkinsonism and Related Disorders*, **2019**, 62, 210-214	3.6	6
71	Olfaction in patients with isolated REM sleep behavior disorder who eventually develop multiple system atrophy. *Sleep*, **2020**, 43,	1.1	5
70	Overlaps between multiple system atrophy and multiple sclerosis: A novel perspective. *Movement Disorders*, **2016**, 31, 1767-1771	7	5
69	Cognition in a multiple system atrophy series of cases from Argentina. *Arquivos De Neuro-Psiquiatria*, **2014**, 72, 773-6	1.6	5
68	Multiple system atrophy masking multiple sclerosis. *Clinical Neurology and Neurosurgery*, **2010**, 112, 59-61	1	5
67	Disproportionate antecollis: a warning sign for multiple system atrophy. *Movement Disorders*, **2007**, 22, 1986; author reply 1986-7	7	5

66	Signs of Chronic Hypoxia Suggest a Novel Pathophysiological Event in -Synucleinopathies. *Movement Disorders*, **2020**, 35, 2333-2338	7	5
65	Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment. *Parkinsonism and Related Disorders*, **2021**, 86, 124-132	3.6	5
64	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. *Parkinsonism and Related Disorders*, **2021**, 82, 87-91	3.6	5
63	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. *Clinical Autonomic Research*, **2021**, 31, 157-164	4.3	5
62	TNF-inhibitors as targets for protective therapies in MSA: a viewpoint. *Journal of Neuroinflammation*, **2019**, 16, 80	10.1	4
61	Overexpression of -synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. *BMC Neuroscience*, **2015**, 16, 86	3.2	4
60	Emergent creativity in frontotemporal dementia. *Journal of Neural Transmission*, **2021**, 128, 279-293	4.3	4
59	Very late-onset pure autonomic failure. *Movement Disorders*, **2017**, 32, 1106-1108	7	3
58	Rifampicin for multiple system atrophy. *Lancet Neurology, The*, **2014**, 13, 237-9	24.1	3
57	The diagnosis of multiple system atrophy. *Journal of Neurology*, **2006**, 253, iii2-iii15	5.5	3
56	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [C]PBR28 and Machine Learning Analysis. *Movement Disorders*, **2021**,	7	3
55	Characterization of gait variability in multiple system atrophy and Parkinson's disease. *Journal of Neurology*, **2021**, 268, 1770-1779	5.5	3
54	Cardiovascular autonomic testing in the work-up of cerebellar ataxia: insight from an observational single center study. *Journal of Neurology*, **2020**, 267, 1097-1102	5.5	3
53	Laboratory-Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group. *Movement Disorders Clinical Practice*, **2021**, 8, 322-340	2.2	3
52	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. *Movement Disorders*, **2021**, 36, 241-245	7	3
51	Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study. *Movement Disorders Clinical Practice*, **2021**, 8, 1052-1060	2.2	3
50	Is Multiple System Atrophy a Prion-like Disorder?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
49	Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. *Clinical Autonomic Research*, **2019**, 29, 385-395	4.3	2

48	Effects of self-administered cannabidiol in a patient with multiple system atrophy. *Clinical Autonomic Research*, **2020**, 30, 355-356	4.3	2
47	Autonomic failure in CANVAS syndrome. *Brain*, **2014**, 137, 2625-6	11.2	2
46	Modelling progressive autonomic failure in MSA: where are we now?. *Journal of Neural Transmission* , **2011**, 118, 841-7	4.3	2
45	Etiology, Pathology, and Pathogenesis. *Blue Books of Neurology*, **2010**, 34, 321-339		2
44	Multiple system atrophy **2005**, 623-662		2
43	Instrumented gait analysis defines the walking signature of CACNA1A disorders. *Journal of Neurology*, **2021**, 1	5.5	2
42	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. *Parkinsonism and Related Disorders*, **2021**, 85, 30-36	3.6	2
41	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease. *Movement Disorders*, **2021**, 36, 449-459	7	2
40	ATH434 Reduces -Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy. *Movement Disorders*, **2021**, 36, 2605-2614	7	2
39	Current experimental disease-modifying therapeutics for multiple system atrophy. *Journal of Neural Transmission*, **2021**, 128, 1529-1543	4.3	2
38	Toll-like receptor 4 deficiency facilitates -synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease. *Parkinsonism and Related Disorders*, **2021**, 91, 59-65	3.6	2
37	Conjugal multiple system atrophy: Rethinking numbers of probability. *Parkinsonism and Related Disorders*, **2020**, 77, 176-177	3.6	1
36	The footprint of orthostatic hypotension in parkinsonian syndromes. *Parkinsonism and Related Disorders*, **2020**, 77, 107-109	3.6	1
35	Is Multiple System Atrophy a New Prion Disorder?. *Movement Disorders*, **2016**, 31, 300	7	1
34	Which way does the axis tip? IBD increases the risk of Parkinson's disease. *Gut*, **2019**, 68, 3	19.2	1
33	Corticobasal degeneration75-98		1
32	Parkinson-Plus Disorders **2008**, 157-175		1
31	Is peripheral neuropathy a feature of multiple system atrophy?. *Clinical Autonomic Research*, **2001**, 11, 63	4.3	1

30	Autonomic History Taking and Key Symptoms: Where Is the Autonomic Disease? **2017**, 15-36		1
29	Commentary: Discriminating -synuclein strains in parkinson's disease and multiple system atrophy. *Frontiers in Neuroscience*, **2020**, 14, 802	5.1	1
28	Neuropathology of multiple system atrophy: Kurt Jellinger's legacy. *Journal of Neural Transmission*, **2021**, 128, 1481-1494	4.3	1
27	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. *Movement Disorders*, **2021**, 36, 2703-2705	7	1
26	Female sexual dysfunction in multiple system atrophy: a prospective cohort study. *Clinical Autonomic Research*, **2021**, 31, 713-717	4.3	1
25	Autonomic failure: a neglected presentation of Parkinson's disease. *Lancet Neurology, The*, **2021**, 20, 781-782	24.1	1
24	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy.. *Clinical Autonomic Research*, **2022**, 1	4.3	0
23	The role of cardiovascular autonomic failure in the differential diagnosis of -synucleinopathies. *Neurological Sciences*, **2021**, 43, 187	3.5	0
22	Reliability and validity of Japanese version of Unified Multiple System Atrophy Rating Scale. *Neurology and Clinical Neuroscience*, **2021**, 9, 171-180	0.3	0
21	Multiple system atrophy in the USA: another piece in the jigsaw. *Lancet Neurology, The*, **2015**, 14, 672-4	24.1	
20	Animal Models of Multiple-System Atrophy **2015**, 887-904		
19	Which Autonomic Features Distinguish Multiple System Atrophy and When. *Movement Disorders*, **2020**, 35, 902-903	7	
18	Evidenzbasierte Therapie der neurogenen orthostatischen Hypotonie. *InFo Neurologie & Psychiatrie*, **2016**, 18, 36-43	0	
17	Multiple System Atrophy (MSA) **2013**, 2119-2141		
16	Magnetic resonance imaging of multiple system atrophy167-203		
15	Multiple system atrophy1-15		
14	Parkinsonism other causes99-125		
13	The differential diagnosis of parkinsonism: A clinical approach126-141		

12	No need to droop your head in Parkinson's disease?. *Parkinsonism and Related Disorders*, **2009**, 15, 620	3.6
11	Multiple System Atrophy (MSA) **2022**, 2409-2432	
10	Combination Lesion Models of MSA. *Neuromethods*, **2011**, 37-54	0.4
9	Clinical Presentation **2014**, 97-119	
8	Clinical Diagnostic Criteria **2014**, 121-132	
7	Preface. *Movement Disorders*, **2016**, 31, 151	7
6	Parkinsonism and dysautonomia: Multiple system atrophy?. *Parkinsonism and Related Disorders*, **2020**, 77, 150-151	3.6
5	Cardiovascular autonomic failure in Parkinson's disease. *International Review of Movement Disorders*, **2021**, 1, 119-146	
4	Parkinson's disease and the spectrum of Lewy body disease10-26	
3	Multiple system atrophy27-57	
2	Progressive supranuclear palsy58-74	
1	Non-pharmacological treatment for atypical parkinsonism142-159	